AI assistant
REPLIGEN CORP — Director's Dealing 2022
Mar 3, 2022
30826_dirs_2022-03-02_1287b0b0-3da5-49f8-aff9-089907a15965.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2022-03-01
Reporting Person: RYAN THOMAS F JR (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-01 | Common Stock | M | 1000 | $38.76 | Acquired | 3457 | Direct |
| 2022-03-01 | Common Stock | S | 1000 | $198.48 | Disposed | 2457 | Direct |
| 2022-03-01 | Common Stock | S | 1000 | $197.58 | Disposed | 1457 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-03-01 | Stock Option (Right to Buy) | $38.76 | M | 1000 | Acquired | 2030-11-11 | Common Stock (1000) | Direct |
Footnotes
F1: The total reported in Column 5 has been adjusted to correct an overstatement of total holdings by 9,880 shares, first reflected in a Form 4 filed on November 2, 2021.
F2: $198.48 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.19 to $198.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option is currently exercisable.